Women who inject drugs are vulnerable to endocarditis, study shows

Japan­ese drug­mak­er Ono Phar­ma­ceu­ti­cal is ac­quir­ing can­cer-fo­cused biotech De­ci­phera Phar­ma­ceu­ti­cals for $2.4 bil­lion, the com­pa­nies an­nounced Mon­day morn­ing. The deal will see Ono ac­quire all

Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are